Not long after the departure of…
Not long after the departure of former CEO Usman Azam, [...]
Not long after the departure of former CEO Usman Azam, [...]
With an eye on the lucrative U.S. market, Italy’s Angelini [...]
BeOne Medicines has shaken up its early pipeline, dropping five [...]
After a surprise rejection in January, the FDA has agreed [...]
Ascendis Pharma has ended internal development of its IL-2 candidate, [...]
For people living with exocrine pancreatic insufficiency due to cystic [...]
Entrada Therapeutics’ Duchenne muscular dystrophy data have fallen well short [...]
The recent run of first-quarter earnings results marked a shift [...]
Against expert advice, people are using new and unpredictable synthetic [...]
A Bristol Myers Squibb plant that makes cancer drugs was [...]